Nicotinic acetylcholine receptor

$16 Million Capital Raise to Progress Bionomics BNC210 PTSD Trial

Retrieved on: 
Wednesday, February 10, 2021
Branches of biology, Nicotinic antagonists, Medical specialties, Anxiolytics, BNC-210, Dipeptides, Psychoactive drugs, Merck & Co., Nicotinic acetylcholine receptor, Post-traumatic stress disorder

Bionomics' lead drug BNC210 has already received Fast Track Designation from the FDA and I am confident of the strong potential of the upcoming Phase 2b PTSD trial to drive value for both patients and shareholders."

Key Points: 
  • Bionomics' lead drug BNC210 has already received Fast Track Designation from the FDA and I am confident of the strong potential of the upcoming Phase 2b PTSD trial to drive value for both patients and shareholders."
  • Bionomics' lead drug candidate BNC210, currently in development for initiation of a second Phase 2 trial for the treatment of PTSD, is a novel, proprietary negative allosteric modulator of the alpha-7 (7) nicotinic acetylcholine receptor.
  • Beyond BNC210, Bionomics has a strategic partnership with Merck & Co., Inc (known as MSD outside the United States and Canada).
  • Results of studies performed on our drug candidates and competitors' drugs and drug candidates may vary from those reported when tested in different settings.

Achieve Life Sciences to Host Smoking Cessation Key Opinion Leader Virtual Roundtable on November 17th, 2020

Retrieved on: 
Tuesday, October 27, 2020
Smoking cessation, Branches of biology, Psychoactive drugs, Nicotinic agonists, Organic compounds, Smoking, Teratogens, Health effects of tobacco, Varenicline, Nicotine, Nicotinic acetylcholine receptor, Acetylcholine receptor

SEATTLE andVANCOUVER, BC, Oct. 27, 2020 /PRNewswire/ --Achieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced the Company will host a Key Opinion Leader (KOL) virtual roundtable event on cytisinicline and smoking cessation on Tuesday, November 17th, 2020, at 12:00PM EST.

Key Points: 
  • SEATTLE andVANCOUVER, BC, Oct. 27, 2020 /PRNewswire/ --Achieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced the Company will host a Key Opinion Leader (KOL) virtual roundtable event on cytisinicline and smoking cessation on Tuesday, November 17th, 2020, at 12:00PM EST.
  • The event will include an overview by the principal investigator of the ongoing ORCA-2 Phase 3 clinical trial of cytisinicline and provide a review of the results from the RAUORA head-to-head study of cytisinicline vs. Chantix(varenicline).
  • Cytisinicline is a plant-based alkaloid with a high binding affinity to the nicotinic acetylcholine receptor.
  • It is believed to aid in smoking cessation by interacting with nicotine receptors in the brain by reducing the severity of nicotine withdrawal symptoms and by reducing the reward and satisfaction associated with smoking.

Achieve Life Sciences Announces Results from Evaluation of Cytisinicline (cytisine) versus Chantix® (varenicline) in 5-HT3 Receptor Binding Assay Study

Retrieved on: 
Friday, September 18, 2020
Branches of biology, Psychoactive drugs, Drugs, Nicotinic agonists, Cell signaling, Euphoriants, Nicotinic antagonists, Pharmacodynamics, Varenicline, Nicotinic acetylcholine receptor, Acetylcholine receptor, Nicotine

Using a radioligand antagonist displacement design, the study reported an IC50 of 0.50 mM for cytisinicline and 0.25 M for varenicline, representing a 2000-greater fold agonist binding affinity to the 5-HT3 receptor for varenicline compared to cytisinicline.

Key Points: 
  • Using a radioligand antagonist displacement design, the study reported an IC50 of 0.50 mM for cytisinicline and 0.25 M for varenicline, representing a 2000-greater fold agonist binding affinity to the 5-HT3 receptor for varenicline compared to cytisinicline.
  • "It is well-established that agonist activation of 5-HT3 receptors in the brain stem directly leads to nausea and vomiting.
  • Achieve's focus is to address the global smoking health and nicotine addiction epidemic through the development and commercialization of cytisinicline.
  • Cytisinicline is a plant-based alkaloid with a high binding affinity to the nicotinic acetylcholine receptor.

Bionomics and MSD Scientists Publish Preclinical Findings for BNC375 in Peer-Reviewed Journal

Retrieved on: 
Tuesday, March 31, 2020
Biotechnology, Pharmaceutical, Health, Clinical trials, Branches of biology, Neurotransmitters, Nicotinic agonists, Ion channels, Nicotinic antagonists, Anxiolytics, Cell signaling, BNC-210, Nicotinic acetylcholine receptor, Acetylcholine

The paper entitled, Pharmacological characterization of the novel and selective 7 nicotinic acetylcholine receptor positive allosteric modulator BNC375, is authored by scientists from MSD and Bionomics Limited.

Key Points: 
  • The paper entitled, Pharmacological characterization of the novel and selective 7 nicotinic acetylcholine receptor positive allosteric modulator BNC375, is authored by scientists from MSD and Bionomics Limited.
  • The paper presents data from a comprehensive range of pre-clinical studies performed with BNC375 to explore the potential of this novel molecule to improve cognitive impairment.
  • Bionomics Executive Chairman, Dr Errol De Souza said, Data from our collaboration with MSD on BNC375 targeting cognitive impairment has been published in this peer-reviewed journal.
  • Beyond BNC210, Bionomics has a strategic partnership with MSD and a pipeline of pre-clinical ion channel programs targeting pain, depression, cognition and epilepsy.

Oyster Point Pharma to Present at the Cowen 40th Annual Healthcare Conference

Retrieved on: 
Monday, February 24, 2020
Branches of biology, Psychoactive drugs, Acetylcholine, Nicotinic agonists, Ion channels, Stimulants, Nicotinic antagonists, Quaternary ammonium compounds, Nicotinic acetylcholine receptor, Nicotine

To access the live webcast of the presentation, please visit the Events & Presentations page within the Investors section of the Oyster Point Pharma website at https://investors.oysterpointrx.com/ .

Key Points: 
  • To access the live webcast of the presentation, please visit the Events & Presentations page within the Investors section of the Oyster Point Pharma website at https://investors.oysterpointrx.com/ .
  • Replays of the webcast will be available on the Oyster Point Pharma website for approximately 30 days following the presentation.
  • Oyster Point Pharma is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases.
  • Oyster Point Pharmas lead product candidate, OC-01 nasal spray, a highly selective nicotinic acetylcholine receptor (nAChR) agonist, is being developed as a nasal spray to treat the signs and symptoms of dry eye disease.

Oyster Point Pharma’s OC-01 Nasal Spray Meets Primary Endpoint in Phase 2 Mystic Trial in Subjects With Dry Eye Disease

Retrieved on: 
Monday, January 13, 2020
Branches of biology, Neurotransmitters, Nicotinic agonists, Nicotinic antagonists, Nose, Dosage forms, Quaternary ammonium compounds, Nicotinic acetylcholine receptor, Nasal spray, Nicotine, Acetylcholine

We look forward to discussing top-line data from our Phase 3 ONSET-2 study in Dry Eye Disease in mid-2020.

Key Points: 
  • We look forward to discussing top-line data from our Phase 3 ONSET-2 study in Dry Eye Disease in mid-2020.
  • The study compared two different doses of OC-01 nasal spray to vehicle control nasal spray (1:1:1 randomization).
  • Oyster Point Pharmas lead product candidate, OC-01 nasal spray, a highly selective nicotinic acetylcholine receptor (nAChR) agonist, is being developed as a nasal spray to treat the signs and symptoms of dry eye disease.
  • Dry eye disease is a chronic, progressive condition that impacts more than 30 million Americans and is growing in prevalence.

Oyster Point Pharma to Present at the 38th Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Tuesday, December 17, 2019
Branches of biology, Psychoactive drugs, Acetylcholine, Nicotinic agonists, Ion channels, Stimulants, Nicotinic antagonists, Quaternary ammonium compounds, Nicotinic acetylcholine receptor, Nicotine

To access the live webcast of the presentation, please visit the Events & Presentations page within the Investors section of the Oyster Point Pharma website at https://investors.oysterpointrx.com/ .

Key Points: 
  • To access the live webcast of the presentation, please visit the Events & Presentations page within the Investors section of the Oyster Point Pharma website at https://investors.oysterpointrx.com/ .
  • Replays of the webcast will be available on the Oyster Point Pharma website for 30 days following the presentation.
  • Oyster Point Pharma is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases.
  • Oyster Point Pharmas lead product candidate, OC-01 nasal spray, a highly selective nicotinic acetylcholine receptor (nAChR) agonist, is being developed as a nasal spray to treat the signs and symptoms of dry eye disease.

Sale of Bionomics’ French Subsidiaries to Domain Therapeutics

Retrieved on: 
Wednesday, December 11, 2019
Biotechnology, Pharmaceutical, Health, Clinical trials, Branches of biology, Cell signaling, Nicotinic antagonists, Anxiolytics, BNC-210, Dipeptides, Ion channels, Nicotinic acetylcholine receptor, Receptor

The sale price of 1,810,028.97 is the amount of intercompany debt owed by Bionomics to the subsidiaries for the scientific research conducted by them on Bionomics drug candidates and this debt will be assumed by Domain upon acquisition of the Companies.

Key Points: 
  • The sale price of 1,810,028.97 is the amount of intercompany debt owed by Bionomics to the subsidiaries for the scientific research conducted by them on Bionomics drug candidates and this debt will be assumed by Domain upon acquisition of the Companies.
  • We are pleased with the outcome of the sale of our French subsidiaries which is part of our ongoing cost reduction process, consolidation of our operations in Adelaide and focus on the clinical development of BNC210 for post-traumatic stress disorder, said Dr. Errol De Souza, Executive Chairman of Bionomics.
  • The offer from Domain is subject to satisfaction of a number of conditions precedent, including entering into definitive contractual documentation satisfactory to both parties and regulatory approval.
  • Bionomics lead drug candidate BNC210 is a novel, proprietary negative allosteric modulator of the alpha-7 (7) nicotinic acetylcholine receptor.

Oyster Point Pharma to Present at the 31st Annual Piper Jaffray Healthcare Conference

Retrieved on: 
Monday, November 25, 2019
Branches of biology, Psychoactive drugs, Acetylcholine, Nicotinic agonists, Ion channels, Stimulants, Nicotinic antagonists, Quaternary ammonium compounds, Nicotinic acetylcholine receptor, Nicotine

To access the live webcast of the presentation, please visit the Events & Presentations page within the Investors section of the Oyster Point Pharma website at https://investors.oysterpointrx.com/ .

Key Points: 
  • To access the live webcast of the presentation, please visit the Events & Presentations page within the Investors section of the Oyster Point Pharma website at https://investors.oysterpointrx.com/ .
  • Replays of the webcast will be available on the Oyster Point Pharma website for 30 days following the presentation.
  • Oyster Point Pharma is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases.
  • Oyster Point Pharmas lead product candidate, OC-01 nasal spray, a highly selective nicotinic acetylcholine receptor (nAChR) agonist, is being developed as a nasal spray to treat the signs and symptoms of dry eye disease.

Oyster Point Pharma to Present at the BIO CEO & Investor Conference

Retrieved on: 
Thursday, January 24, 2019
Health, Biotechnology, Clinical trials, Optical, Pharmaceutical, Branches of biology, Acetylcholine, Neurotransmitters, Ion channels, Nicotinic agonists, Autoantigens, Cell signaling, Nicotinic acetylcholine receptor, Acetylcholine receptor

Oyster Point Pharma, Inc., a privately held clinical-stage pharmaceutical company with an initial focus on developing novel therapies for the treatment of Dry Eye Disease, today announced that Jeffrey Nau, M.M.S., Ph.D., President and CEO, is scheduled to present a corporate overview at the BIO CEO & Investor Conference on Tuesday, February 12th, 2019 at 10:30 a.m. EST in New York.

Key Points: 
  • Oyster Point Pharma, Inc., a privately held clinical-stage pharmaceutical company with an initial focus on developing novel therapies for the treatment of Dry Eye Disease, today announced that Jeffrey Nau, M.M.S., Ph.D., President and CEO, is scheduled to present a corporate overview at the BIO CEO & Investor Conference on Tuesday, February 12th, 2019 at 10:30 a.m. EST in New York.
  • Oyster Point Pharma is a clinical-stage pharmaceutical company leveraging neuroscience to discover, develop, and commercialize novel therapies to treat diseases with high unmet needs.
  • Oyster Point is leveraging a class of molecules called nicotinic acetylcholine receptor (nAChR) agonists to bind receptors on the trigeminal nerve, accessible within the nose, to stimulate natural tear film production.
  • View source version on businesswire.com: https://www.businesswire.com/news/home/20190124005517/en/